Funding Status:
Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
|
|
Aims:
Robust identification of current research that identifies both pre-mission risks and vulnerabilities for individuals due to family history, previous exposures, preventive medicine, sensitivites, genotype and phenotype within the context of integrated risk and risks posed to crew health and safety and the countermeaaures needed should medical conditions arise. For example, in major depressive disorder, high levels of histone deacetylase 5 prior to treatment initiation appear to be a robust marker for treatment response (Iga et al., 2007; Hobara et al., 2010; Belzeaux et al., 2010). Levels of cyclic-adenosine monophosphate (cAMP) response element binding protein 1 (Iga et al., 2007), histone deacetylase 2 (Hobara et al., 2010), serotonergic markers (Belzeaux et al., 2010), a panel of four gene expression pro les (Belzeaux et al., 2012), and interferon regulatory factor 7 (Mamdani et al., 2011) have variously been reported to change following treatment with antidepressants.
-Belzeaux R, Formisano-Tre´ziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, Fe´ron F, Naudin J, Ibrahim EC (2010) Clinical variations modulate patterns of gene expression and de ne blood biomarkers in major depression. J Psychiatr Res 44:1205–1213.
-Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, Gabert J, Nguyen C, Azorin JM, Naudin J, Ibrahim EC (2012) Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2:e185.
-Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, Suetsugi M, Watanabe Y (2010) Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 44:263–270.
-Iga Ji, Ueno Si, Yamauchi K, Numata S, Kinouchi S, Tayoshi- Shibuya S, Song H, Ohmori T (2007) Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 31:628–632.
-Mamdani F, Berlim MT, Beaulieu MM, Labbe A, Merette C, Turecki G (2011) Gene expression biomarkers of response to citalo- pram treatment in major depressive disorder. Transl Psychiatry 1:e13.